Abstract. In vitro studies have demonstrated that thyroid hormones can enhance basal and stimulated growth hormone secretion by cultured pituitary cells. However, both in man and in the rat the effects of high thyroid hormone levels on GH secretion are unclear. The aim of our study was to test the GH response to human GHRH in hyperthyroid patients and to evaluate the effects on GH secretion of short-and long-term pharmacological decrease of circulating thyroid hormones. We examined 10 hyperthyroid patients with recent diagnosis of Graves' disease. Twelve healthy volunteers served as controls. All subjects received a bolus iv injection of GHRH(1-29)NH2, 100 \g=m\g.Hyperthyroid patients underwent a GHRH test one and three months after starting antithyroid therapy with methimazole, 10 mg/day po. GH levels at 15, 30, 45, 60 min and GH peak after stimulus were significantly lower in hyperthyroid patients than in normal subjects. The GH peak was also delayed in hyperthyroid patients. After one month of methimazole therapy, most of the hyperthyroid patients had thyroid hormone levels in the normal range, but they did not show significant changes in GH levels after GHRH, and the GH peak was again delayed. After three months of therapy with methimazole, the hyperthyroid patients did not show a further significant decrease in serum thyroid hormone levels. However, mean GH levels from 15 to 60 min were significantly increased compared with the control study. The GH peak after GHRH was also earlier than in the pretreatment study. In conclusion, the GH response to GHRH is inhibited and delayed by hyperthyroidism and returns to the normal pattern after long-term euthyroidism has been achieved with methimazole.
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Growth hormone synthesis and secretion are reg¬ ulated by the hypothalamic peptides GH-releasing hormone, which has an excitatory role, and soma¬ tostatin, which has an inhibitory role (1) . Several peptides and monoamines are able to affect GH secretion, usually by influencing GHRH and/or so¬ matostatin secretion and action (2) .
In vitro studies demonstrate that thyroid hor¬ mones enhance basal and stimulated GH secretion by cultured pituitary cells (3, 4) . Hypothyroidism causes a decreased GH response to GHRH in humans which returns to normal in the euthyroid state (5, 6) . However, both in man and in rat, the effects of high thyroid hormone levels on GH secretion are unclear. In hyperthyroid patients either normal (7) or reduced (8, 9 ) GH responses to pharmacological stimuli are described; reduced spontaneous nocturnal GH secretion in hyperthy¬ roid men has also been reported (10) . In the hy¬ perthyroid rat the GH response to GHRH has been described to be either decreased (11) (4.3, 3.8-6.4 mmol/1). However, mean absolute GH levels from 15 to 60 min were significantly increased compared with the hyperthyroid status and with one month methimazole therapy (Fig. 1) . The median GH peak after GHRH was not significantly different from that of normal subjects (15.5, 5.7-30 (16) .
In vivo studies have shown that in hypothyroid rats GH synthesis and secretion are decreased (11, 12, (17) (18) (19) . Hypothyroid humans also show re¬ duced GH responses to various stimuli, such as in¬ sulin-induced hypoglycemia, arginine and GHRH.
The GH response to these stimuli returns to normal in the euthyroid state (5, 6, 20, 21) .
The effect of elevated thyroid hormones levels on GH secretion has been studied in vivo by several authors with conflicting results. In the rat, pretreating animals with thyroxine has been reported to decrease the GH response to GHRH compared with the euthyroid state (11) . However, other authors could not find any significant impairment of G H secretion in the same animal model (12) .
In man, several studies have reported that hy¬ perthyroid patients have reduced spontaneous sleep-induced GH surges (22) , and the GH re¬ sponse to various stimuli, such as insulin-induced hypoglycemia (8, 9) and beta-adrenergic blockers (23, 24) is impaired. The GH response to GHRH in hyperthyroid patients has been reported either to be blunted (14) or normal (13) .
On the basis of our data we can confirm that the GH response to GHRH in hyperthyroid patients is impaired as well as delayed compared with that in normal subjects. We can also add that one month of methimazole administration does not affect the pattern of GH secretion, whereas long-term druginduced euthyroidism returns the GH response to GHRH to the pattern observed in healthy subjects.
In a previous study (13) , the GH response to GHRH in a group of hyperthyroid patients was of a similar magnitude to the response we observed in our patients. However, the former study did not report GH values for normal subjects. This differ¬ ence in experimental design may explain the dif¬ ferent conclusions reached.
The mechanism by which the elevation in the serum concentration of thyroid hormones causes prolonged inhibition of GH secretion remains to be explained. On the basis of our results it seems un¬ likely that it is mediated by a decrease of hypotha¬ lamic secretion of GHRH. We can hypothesize that, as glucocorticoids (25) , thyroid hormones may have a dichotomic effect on growth hormone secretion: in fact, hypothyroid patients (5, 6, 20, 21) as well as patients with ACTH deficiency (26) (27) , the GH response to GHRH is inhibited. It may be suggested that in both situations the hypothalamic somatostatin tone may be enhanced (14, 28, 29 (30, 31) appears to be longer than that necessary for the recovery of the GH response to GHRH. How¬ ever, the impaired GH secretion after one month of methimazole therapy may be explained, at least in 2 of our patients, by the presence at that time of still elevated serum thyroid hormone levels.
In conclusion, the GH response to GHRH is in¬ hibited and delayed by hyperthyroidism and re¬ turns to normal after long-term euthyroidism has been achieved by methimazole treatment.
